Form 8-K - Current report:
SEC Accession No. 0001193125-25-035114
Filing Date
2025-02-25
Accepted
2025-02-25 16:01:22
Documents
14
Period of Report
2025-02-24
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d830385d8k.htm   iXBRL 8-K 28869
  Complete submission text file 0001193125-25-035114.txt   181141

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA grtx-20250224.xsd EX-101.SCH 3221
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE grtx-20250224_def.xml EX-101.DEF 13336
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE grtx-20250224_lab.xml EX-101.LAB 21785
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grtx-20250224_pre.xml EX-101.PRE 14092
17 EXTRACTED XBRL INSTANCE DOCUMENT d830385d8k_htm.xml XML 5184
Mailing Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355
Business Address 101 LINDENWOOD DRIVE SUITE 225 MALVERN PA 19355 610-725-1500
Galera Therapeutics, Inc. (Filer) CIK: 0001563577 (see all company filings)

EIN.: 461454898 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39114 | Film No.: 25662882
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)